Detalhe da pesquisa
1.
5-HT5A Receptor Antagonist ASP5736 Ameliorates Several Abnormal Behaviors in an Fmr1-Targeted Transgenic Male Rat Model of Fragile X Syndrome.
Int J Neuropsychopharmacol
; 25(9): 786-793, 2022 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35882205
2.
Optimization and biological evaluation of imidazopyridine derivatives as a novel scaffold for γ-secretase modulators with oral efficacy against cognitive deficits in Alzheimer's disease model mice.
Bioorg Med Chem
; 28(11): 115455, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32307259
3.
Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats.
J Pharmacol Sci
; 127(3): 362-9, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25837935
4.
Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.
J Neurosci
; 32(6): 2037-50, 2012 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22323718
5.
Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aß42 without affecting other Aß pools.
J Neurochem
; 125(3): 465-72, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23240999
6.
The evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia.
Proc Natl Acad Sci U S A
; 105(16): 6133-8, 2008 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-18413613
7.
Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia.
Eur Neuropsychopharmacol
; 28(5): 620-629, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29571967
8.
Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3.
Eur J Pharmacol
; 810: 26-35, 2017 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28552344
9.
ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia.
Eur Neuropsychopharmacol
; 24(10): 1698-708, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25108314
10.
Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
Neuropharmacology
; 79: 412-9, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24373902
11.
Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Eur J Pharmacol
; 703(1-3): 53-61, 2013 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-23276665
12.
A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.
Eur J Pharmacol
; 685(1-3): 59-69, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22542656
13.
Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
J Pharmacol Exp Ther
; 323(2): 708-19, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17684118
14.
A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P.
J Biol Chem
; 277(43): 41254-8, 2002 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-12185074